Health Desk
Mifepristone manufacturers Danco Laboratories and GenBioPro have filed an emergency application with the U.S. Supreme Court, seeking to restore nationwide access to a primary medication used in early-stage abortions and miscarriage management. This legal maneuver follows a ruling by the 5th U.S. Circuit Court of Appeals on Friday, which effectively reinstated significant restrictions that the Food and Drug Administration (FDA) had lifted over the past several years.
The appellate court’s decision suspended FDA regulations that allowed the drug to be prescribed via telehealth and delivered to patients through the mail. Without intervention from the High Court, the ruling forces a return to a 2011 regulatory framework. This older standard requires patients to make three in-person clinical visits to obtain the medication, a requirement the FDA had previously deemed medically unnecessary.
Danco Laboratories argued in its filing that the sudden regulatory shift creates “untenable” instability for healthcare providers and patients alike. The company warned that the ruling “injects immediate confusion and upheaval” into a time-sensitive medical process. Generic manufacturer GenBioPro joined the appeal, emphasizing that the lower court’s decision undermines the FDA’s scientific authority to regulate drug safety and distribution—a precedent that could impact the broader pharmaceutical industry.
This case marks the most significant legal challenge to reproductive healthcare in the United States since the 2022 overturning of Roe v. Wade. The Supreme Court’s pending decision will determine whether the drug remains accessible via mail while the full legal challenge continues to move through the judicial system.
In its filing, GenBioPro said that “patients and clinicians have, for years, relied on dispensing mifepristone without an in-clinic visit, particularly for women from rural areas and those for whom transportation, child care or occupational constraints make it difficult to see providers in person.”
Regulatory Timeline and Impact
| Year | FDA Action | Current Status (Per Appeals Court) |
| 2016 | Usage window extended from 7 to 10 weeks of pregnancy. | Rollback: Restored to 7 weeks. |
| 2021 | In-person dispensing requirement permanently lifted. | Suspended: In-person visits now mandatory. |
| 2023 | Mail-order pharmacy distribution authorized. | Halted: Delivery by mail is prohibited. |